Identification of alternative splice variants and changes in patterns of alternative splicing involved in cancer by bioinformatic analysis and expression studies

The Human Genome Project identified approximately 25,000 genes in human DNA, which was much less than expected. However, about 60 percent of these genes undergo alternative splicing, in which one gene is assembled from its component pieces in many different ways. This phenomenon enables genes to have incredibly diverse variations that represent hundreds of thousands of functional units. Malachi Griffith is studying how changes in certain genes due to alternative splicing may have an important role in cancer progression and could account for differences in the severity of the disease from one individual to another. Malachi is comparing large sets of data from genes in healthy individuals and cancer patients to determine if differences in gene forms help explain the causes of different cancers. Findings could contribute to improved diagnosis and treatment of cancer.

Myocardial regeneration with hematopoietic stem cells

Heart attacks are the leading cause of death in the industrialized world. Interest is growing in the use of stem cells to treat the irreversible damage caused by a heart attack. Recent studies have shown hematopoietic stem cells (HSCs), stem cells in the bone marrow, can form heart cells. HSCs are easy to obtain, avoid the ethical issues associated with embryonic stem cells, and their use in bone marrow transplants is well established. The major challenge facing the use of stem cell therapy to treat heart disease is cell survival after transplantation. Heather Heine is comparing different subpopulations of these cells to determine the optimal type to use for treating the heart, how best to administer the stem cells, and how to improve cell survival in the oxygen-depleted environment created by a heart attack. This research could contribute to more effective therapy for improving cardiac function and survival following a heart attack.

Modelling and simulating intra-cellular signalling systems in response to pathogen invasions by semantic networks

Organisms that cause disease use various strategies to create infection. Bacteria such as Mycobacterium tuberculosis invade cells in the human immune system. These bacteria manipulate the internal machinery of a host cell to enter and survive inside the cell. A cell contains many different types of molecules that interact in complex ways to control cell behaviours. Michael Hsing is studying these interactions to understand how bacterial invasions occur. He is using a computer method, called the semantic network, to simulate molecular interactions and cellular behaviours during bacterial invasions. The research could enable researchers to predict how cells respond in different situations, potentially leading to development of drugs to prevent and treat bacterial infections.

GLP-1 gene therapy for Diabetes

Diabetes is a chronic disease that affects more than two million Canadians and 135 million people worldwide. People with this condition are unable to maintain normal blood sugar levels due to a lack of, or insensitivity to, insulin, a hormone that regulates blood sugar levels. Current treatments include insulin injections or oral drugs that stimulate insulin release or improve insulin sensitivity; however, daily administration is required due to their short-term effects. Gene therapy represents an exciting approach in treating diabetes by providing a means to achieve automatic delivery of therapeutic hormones within the body. Glucagon-like peptide-1 (GLP-1) is an intestinal gut hormone with a variety of anti-diabetic effects. Initial clinical studies show that GLP-1 can stimulate insulin production and release. Corinna Lee is examining whether gene therapy could achieve automatic, long-term release of GLP-1 from cells within the body. This research could provide insights into a new method of diabetes treatment that could eliminate the need for daily injections or oral drugs.

Mechanistic investigations of Family 4 Glycosidases

Carbohydrates traditionally were thought to serve one role: reservoirs of energy for maintaining metabolism. In fact, they serve much more diverse and vital roles, including regulation of cellular activity. Vivian Yip is studying Family 4 glycoside hydrolases, a family of enzymes that break down carbohydrates in bacterial cells. These enzymes are part of a system that transports sugar molecules across the cell membrane and into the cell. Inside the cell, the enzymes cut the sugar into smaller pieces to provide food for the bacteria. Vivian is investigating the chemical mechanism of these enzymes, which will provide important clues to inhibiting the enzymes’ activity. Inhibition of these enzymes could restrict the food supply, which would cause bacterial cells to die. Findings from the research could be used to develop antibiotics to reduce bacterial infections with potentially few side effects since currently these enzymes are found only from bacterial sources, but not mammalian.

Role of apoptosis repressor with caspase recruitment domain (ARC) in attenuation of chronic heart transplant rejection associated with transplant vascular disease

More than 2,500 heart transplants are performed worldwide every year. Chronic rejection of the transplanted heart due to transplant vascular disease (TVD) is the greatest obstacle to long-term survival after the operation. TVD causes structural changes in the arteries, leading to blockage that restricts and ultimately cuts blood flow. Despite improvements in anti-rejection drugs, about 40 percent of heart transplant recipients develop the disease within five years. The protein ARC has been shown to prevent death of cardiac cells. Arwen Hunter is investigating the ability of ARC to prevent cell death in blood vessel walls after transplantation. In particular, she is looking at the ways ARC inhibits cell death in blood vessels and ways of optimizing the delivery of ARC into heart tissue. The research could contribute to strategies for preventing organ rejection associated with transplant vascular disease.

Enhancement of melanoma chemosensitivity by adenoviral delivery of PUMA

Melanoma is an aggressive and lethal form of skin cancer that is increasingly prevalent among Caucasians. Although often curable if diagnosed early and surgically removed, melanoma tumors can rapidly metastasize (spread) to other parts of the body. Patients diagnosed with melanoma at later stages face a poor prognosis and survival rates averaging only six to ten months. Once it has spread, melanoma is extremely difficult to treat because it does not respond well to conventional cancer treatments such as radiation and chemotherapy. But the reason for this resistance is unknown. Most anti-cancer drugs induce apoptosis (programmed cell death) in tumor cells. Melanoma may have abnormally high levels of cell survival genes, making them difficult to kill with such drugs. Alison Karst is investigating whether introduction of the PUMA cell death gene into malignant tumors could overcome this problem and sensitize malignant cells to chemotherapy.

Regulating antibiotic resistance in Staphylococcus aureus: elucidation of the mechanism of BlaR1 through X-ray crystallography

The discovery of penicillin in the early 1900s offered the possibility of a “magic bullet” for the treatment of bacterial infection. Bacteria have proven incredibly versatile, however, as new strains have evolved that can overcome the newest and most sophisticated antibiotics. Superbugs are strains of bacteria that are resistant to all available antibiotics. Staphylococcus aureus, also known as Staph, is a normally harmless skin-borne bacterium that can be lethal in patients with weakened immune systems. Strains of Staph function as superbugs that can tolerate all but the newest experimental drugs. As fast as new antibiotics are developed, Staph appears able to evolve resistance to them. Mark Wilke is researching the molecular mechanisms that regulate resistance to a class of antibiotics called beta-lactams. The findings could help explain how Staph bacteria switch their antibiotic resistance on and off, as well as lead to new strategies for combating Staph infections.

Mechanism of myocardial dysfunction in sepsis

More people die each year from sepsis, a severe, overwhelming infection and inflammation, than from breast or colon cancer. The infection is also 20 times more deadly than a heart attack. Septic shock (severe sepsis) causes multiple organ failure and is the leading cause of death in North American intensive care units. Sepsis impairs the heart’s ability to use oxygen, which is necessary for the heart to pump normally. Dr. Ryon Bateman is investigating whether damage to capillaries (the smallest blood vessels) prevents oxygen from being delivered within the heart or whether dysfunction of the mitochondria (the parts of the cell that consume oxygen) prevents oxygen from being used by the heart. Dr. Bateman is using advanced microscopic imaging techniques to generate three-dimensional images of heart capillaries to look for changes in their number and spacing. He is also assessing whether regions of the heart with low oxygen have tissue damage, and if mitochondria are damaged in these regions. The research could explain why the heart is damaged during sepsis, leading to new treatments for critically ill septic patients.

The identification and characterization of candidate Bardet-Biedl Syndrome genes and/or genes specifically involved in ciliary functions

Bardet-Biedl syndrome (BBS) is a complex genetic disease with symptoms that include obesity, blindness and kidney dysfunction. Although seven genes linked to the disease have been cloned, the molecular origin of the syndrome remains unclear. Using Caenorhabitis elegans (a tiny worm) as a model for BBS, Dr. Oliver Blacque’s previous research contributed to the finding that a primary cause of the disease is likely to be malfunctioning cilia, which are finger-like projections that naturally protrude from many human cells. Cilia malfunction has also been shown to cause other conditions including polycystic kidney disease and retinal degeneration. Dr. Blacque is now investigating how cilia operate at the molecular level. He is using tools of bioinformatics (management of biological information with computer technology) and genomics (study of genes) to identify proteins that operate exclusively in cilia and to investigate their functions. The research could improve understanding of the role of cilia in human disease and lead to the discovery of new proteins that cause Bardet-Biedl syndrome and other cilia-related diseases.